ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ACAD Stock Forecast

ACADIA Pharmaceuticals stock forecast is as follows: an average price target of $26.57 (represents a 64.22% upside from ACAD’s last price of $16.18) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.

ACAD Price Target

The average price target for ACADIA Pharmaceuticals (ACAD) is $26.57 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $62.00 to $15.00. This represents a potential 64.22% upside from ACAD's last price of $16.18.

ACAD Analyst Ratings

Buy

According to 18 Wall Street analysts, ACADIA Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ACAD stock is 0 'Strong Buy' (0.00%), 12 'Buy' (66.67%), 5 'Hold' (27.78%), 1 'Sell' (5.56%), and 0 'Strong Sell' (0.00%).

ACADIA Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 07, 2024	Jeffrey Hung	Morgan Stanley	$20.00	$18.85	6.10%	23.61%
Jun 26, 2024	Keith Tapper	BMO Capital	$31.00	$15.50	100.00%	91.59%
May 09, 2024	Andrew Fein	H.C. Wainwright	$27.00	$17.13	57.62%	66.87%
May 09, 2024	Joel Beatty	Robert W. Baird	$28.00	$17.13	63.46%	73.05%
May 09, 2024	Uy Ear	Mizuho Securities	$21.00	$17.13	22.59%	29.79%
Apr 30, 2024	Ashwani Verma	UBS	$27.00	$17.10	57.89%	66.87%
Mar 12, 2024	Ashwani Verma	UBS	$33.00	$19.98	65.17%	103.96%
Mar 12, 2024	Jay Olson	Oppenheimer	$19.00	$19.98	-4.90%	17.43%
Mar 12, 2024	Ami Fadia	Needham	$32.00	$19.98	60.16%	97.78%
Mar 12, 2024	Sumant Kulkami	Canaccord Genuity	$33.00	$19.98	65.17%	103.96%

Row per page

Go to

The latest ACADIA Pharmaceuticals stock forecast, released on Aug 07, 2024 by Jeffrey Hung from Morgan Stanley, set a price target of $20.00, which represents a 6.10% increase from the stock price at the time of the forecast ($18.85), and a 23.61% increase from ACAD last price ($16.18).

ACADIA Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	12
Avg Price Target	-	-	$28.92
Last Closing Price	$16.18	$16.18	$16.18
Upside/Downside	-100.00%	-100.00%	78.74%

In the current month, the average price target of ACADIA Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ACADIA Pharmaceuticals's last price of $16.18. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 17, 2024	Guggenheim	Buy	Buy	Hold
Oct 10, 2024	UBS	Buy	Buy	Hold
Aug 07, 2024	RBC Capital	Equal-Weight	Equal-Weight	Hold
Aug 07, 2024	Morgan Stanley	Overweight	Equal-Weight	Downgrade
Jun 26, 2024	BMO Capital	Buy	Outperform	Initialise
Jun 25, 2024	RBC Capital	Buy	Buy	Hold
May 09, 2024	H.C. Wainwright	Buy	Buy	Hold
Apr 30, 2024	RBC Capital	Buy	Buy	Hold
Apr 30, 2024	UBS	Buy	Buy	Hold
Mar 25, 2024	RBC Capital	Buy	Buy	Hold

Row per page

Go to

ACADIA Pharmaceuticals's last stock rating was published by Guggenheim on Oct 17, 2024. The company gave ACAD a "Buy" rating, the same as its previous rate.

ACADIA Pharmaceuticals Financial Forecast

ACADIA Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$211.70M	$165.24M	$118.46M	$136.49M	$130.71M	$134.56M	$115.47M	$130.76M	$131.61M	$115.22M	$106.55M	$121.01M	$120.58M	$110.10M	$90.07M	$98.33M	$94.59M	$83.20M	$62.96M	$48.87M	$15.29M
Avg Forecast	$271.84M	$265.57M	$256.96M	$232.67M	$276.08M	$248.83M	$235.95M	$208.31M	$223.79M	$192.32M	$166.18M	$120.06M	$134.23M	$138.76M	$130.41M	$121.91M	$135.39M	$127.93M	$124.90M	$112.01M	$122.76M	$118.82M	$103.41M	$90.75M	$96.69M	$88.49M	$72.54M	$60.93M	$61.09M	$15.50M
High Forecast	$325.28M	$317.77M	$307.47M	$242.04M	$367.06M	$248.95M	$235.95M	$208.31M	$228.53M	$192.38M	$198.85M	$143.66M	$160.62M	$138.76M	$130.41M	$121.91M	$135.39M	$127.93M	$124.90M	$112.01M	$122.76M	$118.82M	$103.41M	$90.75M	$96.69M	$88.49M	$72.54M	$60.93M	$73.30M	$18.60M
Low Forecast	$232.70M	$227.33M	$219.96M	$219.90M	$257.05M	$248.71M	$235.95M	$208.31M	$214.31M	$192.26M	$142.25M	$102.77M	$114.91M	$138.76M	$130.41M	$121.91M	$135.39M	$127.93M	$124.90M	$112.01M	$122.76M	$118.82M	$103.41M	$90.75M	$96.69M	$88.49M	$72.54M	$60.93M	$48.87M	$12.40M
# Analysts	3	3	3	5	13	7	7	11	14	7	13	7	6	6	8	6	7	11	7	13	9	9	9	9	5	5	5	5	12	14
Surprise %	-	-	-	-	-	-	-	-	-	1.10%	0.99%	0.99%	1.02%	0.94%	1.03%	0.95%	0.97%	1.03%	0.92%	0.95%	0.99%	1.01%	1.06%	0.99%	1.02%	1.07%	1.15%	1.03%	0.80%	0.99%

ACADIA Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 14 analysts is $223.79M, with a low forecast of $214.31M, and a high forecast of $228.53M. ACAD's average Quarter revenue forecast represents a 5.71% increase compared to the company's last Quarter revenue of $211.70M (Sep 23).

ACADIA Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	3	3	3	5	13	7	7	11	14	7	13	7	6	6	8	6	7	11	7	13	9	9	9	9	5	5	5	5	12	14
EBITDA	-	-	-	-	-	-	-	-	-	$-57.78M	$3.04M	$-53.58M	$-46.06M	$-30.87M	$-33.65M	$-112.50M	$-42.24M	$-13.68M	$-42.34M	$-65.33M	$-64.95M	$-82.91M	$-39.20M	$-84.37M	$-48.73M	$-41.59M	$-53.88M	$-84.14M	$-52.89M	$-87.20M
Avg Forecast	$-121.49M	$-118.69M	$-114.84M	$-103.99M	$-123.39M	$-111.21M	$-105.45M	$-176.77M	$-100.02M	$-85.95M	$-74.27M	$-160.70M	$-40.66M	$-62.54M	$-58.78M	$-146.09M	$-61.02M	$-57.66M	$-56.30M	$-78.89M	$-55.33M	$-53.56M	$-46.61M	$-68.55M	$-43.58M	$-39.88M	$-32.69M	$-72.82M	$-63.47M	$-88.40M
High Forecast	$-104.00M	$-101.60M	$-98.30M	$-98.27M	$-114.88M	$-111.15M	$-105.45M	$-141.42M	$-95.78M	$-85.92M	$-63.57M	$-128.56M	$-32.53M	$-62.54M	$-58.78M	$-116.88M	$-61.02M	$-57.66M	$-56.30M	$-63.11M	$-55.33M	$-53.56M	$-46.61M	$-54.84M	$-43.58M	$-39.88M	$-32.69M	$-58.25M	$-50.77M	$-70.72M
Low Forecast	$-145.37M	$-142.02M	$-137.41M	$-108.17M	$-164.04M	$-111.26M	$-105.45M	$-212.13M	$-102.13M	$-85.98M	$-88.87M	$-192.85M	$-48.79M	$-62.54M	$-58.78M	$-175.31M	$-61.02M	$-57.66M	$-56.30M	$-94.67M	$-55.33M	$-53.56M	$-46.61M	$-82.26M	$-43.58M	$-39.88M	$-32.69M	$-87.38M	$-76.16M	$-106.08M
Surprise %	-	-	-	-	-	-	-	-	-	0.67%	-0.04%	0.33%	1.13%	0.49%	0.57%	0.77%	0.69%	0.24%	0.75%	0.83%	1.17%	1.55%	0.84%	1.23%	1.12%	1.04%	1.65%	1.16%	0.83%	0.99%

7 analysts predict ACAD's average Quarter EBITDA for Sep 23 to be $-85.95M, with a high of $-85.92M and a low of $-85.98M. This is -2930.06% lower than ACADIA Pharmaceuticals's previous annual EBITDA (Jun 23) of $3.04M.

ACADIA Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	3	3	3	5	13	7	7	11	14	7	13	7	6	6	8	6	7	11	7	13	9	9	9	9	5	5	5	5	12	14
Net Income	-	-	-	-	-	-	-	-	-	$-65.18M	$1.11M	$-43.02M	$-41.73M	$-27.18M	$-34.01M	$-113.06M	$-43.09M	$-14.46M	$-43.87M	$-66.45M	$-66.76M	$-84.66M	$-42.14M	$-88.02M	$-53.04M	$-41.98M	$-54.94M	$-85.30M	$-54.30M	$-87.84M
Avg Forecast	$38.50M	$25.64M	$23.98M	$4.51M	$38.37M	$22.95M	$29.52M	$-178.52M	$48.01M	$-74.40M	$-16.25M	$-162.29M	$-41.48M	$-32.27M	$-41.17M	$-147.54M	$-39.48M	$-43.12M	$-50.59M	$-80.24M	$-78.70M	$-63.74M	$-72.98M	$-71.52M	$-60.30M	$-66.77M	$-75.53M	$-73.82M	$-65.16M	$-89.05M
High Forecast	$48.34M	$32.19M	$30.10M	$5.26M	$130.47M	$23.78M	$29.58M	$-142.82M	$88.52M	$-60.47M	$-13.21M	$-129.83M	$-33.18M	$-32.27M	$-41.17M	$-118.03M	$-39.48M	$-43.12M	$-50.59M	$-64.19M	$-78.70M	$-63.74M	$-72.98M	$-57.21M	$-60.30M	$-66.77M	$-75.53M	$-59.06M	$-52.12M	$-71.24M
Low Forecast	$31.29M	$20.84M	$19.49M	$3.76M	$-13.43M	$22.11M	$29.47M	$-214.23M	$34.51M	$-93.41M	$-20.41M	$-194.75M	$-49.77M	$-32.27M	$-41.17M	$-177.05M	$-39.48M	$-43.12M	$-50.59M	$-96.29M	$-78.70M	$-63.74M	$-72.98M	$-85.82M	$-60.30M	$-66.77M	$-75.53M	$-88.58M	$-78.19M	$-106.86M
Surprise %	-	-	-	-	-	-	-	-	-	0.88%	-0.07%	0.27%	1.01%	0.84%	0.83%	0.77%	1.09%	0.34%	0.87%	0.83%	0.85%	1.33%	0.58%	1.23%	0.88%	0.63%	0.73%	1.16%	0.83%	0.99%

ACADIA Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-74.40M, with a range of $-93.41M to $-60.47M. ACAD's average Quarter net income forecast represents a -6778.45% decrease compared to the company's last Quarter net income of $1.11M (Jun 23).

ACADIA Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	3	3	3	5	13	7	7	11	14	7	13	7	6	6	8	6	7	11	7	13	9	9	9	9	5	5	5	5	12	14
SG&A	-	-	-	-	-	-	-	-	-	$97.89M	$95.97M	$101.23M	$104.40M	$78.11M	$89.90M	$96.68M	$105.91M	$81.67M	$96.79M	$111.66M	$120.75M	$81.59M	$84.34M	$101.97M	$91.87M	$72.70M	$67.98M	$93.09M	$60.93M	$65.75M
Avg Forecast	$213.44M	$208.51M	$201.75M	$182.69M	$216.77M	$195.37M	$185.25M	$152.66M	$175.71M	$151.00M	$130.48M	$94.27M	$101.94M	$108.95M	$102.39M	$95.72M	$106.30M	$100.45M	$98.07M	$87.94M	$96.39M	$93.30M	$81.19M	$82.85M	$75.92M	$69.48M	$56.96M	$47.84M	$47.96M	$12.17M
High Forecast	$255.40M	$249.50M	$241.41M	$190.04M	$288.20M	$195.46M	$185.25M	$183.19M	$179.43M	$151.05M	$156.12M	$112.80M	$122.33M	$108.95M	$102.39M	$95.72M	$106.30M	$100.45M	$98.07M	$87.94M	$96.39M	$93.30M	$81.19M	$99.42M	$75.92M	$69.48M	$56.96M	$47.84M	$57.55M	$14.60M
Low Forecast	$182.71M	$178.49M	$172.70M	$172.65M	$201.83M	$195.28M	$185.25M	$122.13M	$168.27M	$150.95M	$111.69M	$80.69M	$81.55M	$108.95M	$102.39M	$95.72M	$106.30M	$100.45M	$98.07M	$87.94M	$96.39M	$93.30M	$81.19M	$66.28M	$75.92M	$69.48M	$56.96M	$47.84M	$38.37M	$9.73M
Surprise %	-	-	-	-	-	-	-	-	-	0.65%	0.74%	1.07%	1.02%	0.72%	0.88%	1.01%	1.00%	0.81%	0.99%	1.27%	1.25%	0.87%	1.04%	1.23%	1.21%	1.05%	1.19%	1.95%	1.27%	5.40%

ACADIA Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $175.71M, based on 14 Wall Street analysts, with a range of $168.27M to $179.43M. The forecast indicates a 79.50% rise compared to ACAD last annual SG&A of $97.89M (Sep 23).

ACADIA Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	3	3	3	5	13	7	7	11	14	7	13	7	6	6	8	6	7	11	7	13	9	9	9	9	5	5	5	5	12	14
EPS	-	-	-	-	-	-	-	-	-	$-0.40	$0.01	$-0.27	$-0.26	$-0.17	$-0.21	$-0.70	$-0.27	$-0.09	$-0.27	$-0.42	$-0.42	$-0.54	$-0.27	$-0.57	$-0.34	$-0.29	$-0.38	$-0.59	$-0.44	$-0.72
Avg Forecast	$0.23	$0.15	$0.14	$0.03	$0.23	$0.14	$0.18	$0.05	$0.29	$-0.45	$-0.10	$-0.21	$-0.25	$-0.19	$-0.25	$-0.62	$-0.24	$-0.26	$-0.30	$-0.53	$-0.47	$-0.38	$-0.44	$-0.48	$-0.36	$-0.40	$-0.45	$-0.52	$-0.66	$-0.74
High Forecast	$0.29	$0.19	$0.18	$0.03	$0.79	$0.14	$0.18	$0.05	$0.53	$-0.36	$-0.08	$-0.17	$-0.20	$-0.19	$-0.25	$-0.62	$-0.24	$-0.26	$-0.30	$-0.53	$-0.47	$-0.38	$-0.44	$-0.48	$-0.36	$-0.40	$-0.45	$-0.52	$-0.53	$-0.59
Low Forecast	$0.19	$0.13	$0.12	$0.02	$-0.08	$0.13	$0.18	$0.05	$0.21	$-0.56	$-0.12	$-0.27	$-0.31	$-0.19	$-0.25	$-0.62	$-0.24	$-0.26	$-0.30	$-0.53	$-0.47	$-0.38	$-0.44	$-0.48	$-0.36	$-0.40	$-0.45	$-0.52	$-0.79	$-0.89
Surprise %	-	-	-	-	-	-	-	-	-	0.89%	-0.07%	1.26%	1.05%	0.88%	0.85%	1.13%	1.14%	0.35%	0.89%	0.79%	0.89%	1.41%	0.61%	1.19%	0.94%	0.72%	0.84%	1.13%	0.67%	0.97%

According to 7 Wall Street analysts, ACADIA Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.45, with a low estimate of $-0.56 and a high estimate of $-0.36. This represents a -6683.82% decrease compared to ACAD previous annual EPS of $0.01 (Jun 23).

ACADIA Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
ATHA	Athira Pharma	$0.66	$18.00	2627.27%	Buy
CABA	Cabaletta Bio	$1.87	$16.33	773.26%	Buy
RVPH	Reviva Pharmaceuticals	$1.24	$10.00	706.45%	Buy
TERN	Terns Pharmaceuticals	$5.71	$14.25	149.56%	Buy
VKTX	Viking Therapeutics	$51.63	$102.40	98.33%	Buy
ACAD	ACADIA Pharmaceuticals	$16.18	$26.57	64.22%	Buy
SRPT	Sarepta Therapeutics	$110.50	$169.06	53.00%	Buy
AKRO	Akero Therapeutics	$31.20	$46.00	47.44%	Buy
BPMC	Blueprint Medicines	$96.62	$109.71	13.55%	Buy
PTCT	PTC Therapeutics	$42.89	$46.50	8.42%	Hold
KRYS	Krystal Biotech	$182.29	$191.00	4.78%	Buy
MDGL	Madrigal Pharmaceuticals	$329.24	$315.75	-4.10%	Buy

ACAD Forecast FAQ

Is ACADIA Pharmaceuticals a good buy?

Yes, according to 18 Wall Street analysts, ACADIA Pharmaceuticals (ACAD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 12 'Buy' recommendations, accounting for 66.67% of ACAD's total ratings.

What is ACAD's price target?

ACADIA Pharmaceuticals (ACAD) average price target is $26.57 with a range of $15 to $62, implying a 64.22% from its last price of $16.18. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ACADIA Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for ACAD stock, the company can go up by 64.22% (from the last price of $16.18 to the average price target of $26.57), up by 283.19% based on the highest stock price target, and down by -7.29% based on the lowest stock price target.

Can ACADIA Pharmaceuticals stock reach $20?

ACAD's average twelve months analyst stock price target of $26.57 supports the claim that ACADIA Pharmaceuticals can reach $20 in the near future.

What are ACADIA Pharmaceuticals's analysts' financial forecasts?

ACADIA Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $969.17M (high $1.06B, low $950.03M), average EBITDA is $-517M (high $-473M, low $-593M), average net income is $-87.677M (high $41.02M, low $-176M), average SG&A $750.05M (high $852.11M, low $704.49M), and average EPS is $0.595 (high $1.16, low $0.278). ACAD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.03B (high $1.19B, low $899.88M), average EBITDA is $-459M (high $-402M, low $-533M), average net income is $92.63M (high $115.9M, low $75.38M), average SG&A $806.39M (high $936.35M, low $706.55M), and average EPS is $0.557 (high $0.697, low $0.454).

Did the ACAD's actual financial results beat the analysts' financial forecasts?

Based on ACADIA Pharmaceuticals's last annual report (Dec 2022), the company's revenue was $517.24M, which missed the average analysts forecast of $525.32M by -1.54%. Apple's EBITDA was $-224M, missing the average prediction of $-308M by -27.42%. The company's net income was $-216M, missing the average estimation of $-262M by -17.71%. Apple's SG&A was $369.09M, missing the average forecast of $409M by -9.76%. Lastly, the company's EPS was $-1.34, beating the average prediction of $-1.307 by 2.52%. In terms of the last quarterly report (Sep 2023), ACADIA Pharmaceuticals's revenue was $211.7M, beating the average analysts' forecast of $192.32M by 10.08%. The company's EBITDA was $-57.776M, missing the average prediction of $-85.949M by -32.78%. ACADIA Pharmaceuticals's net income was $-65.176M, missing the average estimation of $-74.398M by -12.40%. The company's SG&A was $97.89M, missing the average forecast of $151M by -35.17%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.448 by -10.65%